Children's HIV treatment is set to be made available by Aurobindo Pharma in 123 nations

Under a voluntary license from ViiV Healthcare, a pharmaceutical company will introduce its HIV triple combination medicine for children living with HIV in low- and middle-income countries.

The launch of Aurobindo Pharma Ltd's HIV triple combination medicine for children living with HIV in low- and middle-income nations has been announced.

With ViiV Healthcare, Aurobindo holds a paediatric dolutegravir voluntary license. This made it possible for the company to create and distribute this product in 123 low and middle-income countries (LMIC), including India.

The first generic dispersible tablet formulation of the fixed-dose combination Abacavir 60 mg + Lamivudine 30 mg + Dolutegravir 5 mg (pALD) has been given tentative approval by the United States Food and Drug Administration (USFDA), according to a press release from the company. This medication is used to treat children who are HIV-positive.

This is a part of the President's Emergency Plan for AIDS Relief (PEPFAR) initiative of the United States.

The medication will be offered to treat HIV-positive children who weigh 6 kg to 25 kg and are at least three months old. It is used to treat HIV-1, the type 1 human immunodeficiency virus.

The pill would need to be dissolved in water in order to be given. It has a strawberry flavor and may be eaten once a day. The prescribing doctor would choose the appropriate quantity of pills based on the child's weight. 180 pack sizes will be available for multi-month dispensing.

The Drugs Controller General of India (DCGI) has already received Aurobindo's product, which is anticipated to receive approval shortly.

The World Health Organization has identified the dispersible fixed-dose combination of lamivudine, dolutegravir, and abacavir as a priority anti-retroviral treatment (ART) option for children with HIV.

Content source: Media reports